Dyne therapeutics competitors

WebMar 20, 2024 · Dyne Therapeutics is a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically … WebThe Competitors page allows you to view information for other symbols found in the same sector. In the table, you'll find all the components (individual stock symbols) found in that …

DYNE THERAPEUTICS, INC. : DYN Stock Price US26818M1080

WebDyne Therapeutics Inc Working Capital Per Revenue on the trailing twelve month basis from the forth quarter 2024 to forth quarter 2024, Trends and Ranking, Fundamental Ratios - CSIMarket ... Dyne Therapeutics Inc 's Competition Performance; Dyne Therapeutics Inc 's Competitors Results; DYN's Competitors Stock Performance; WebApr 9, 2024 · Dyne Therapeutics, Inc. Competitors. Emergent BioSolutions. NYSE:EBS US$529.5m. 4D Molecular Therapeutics. NasdaqGS:FDMT US$535.7m. Alector. NasdaqGS:ALEC US$518.1m. ARS Pharmaceuticals. NasdaqGM:SPRY US$549.4m. Price History & Performance. ... Dyne Therapeutics, Inc., a muscle disease company, … how did fred hickman die https://webhipercenter.com

Safety, Tolerability, Pharmacodynamic, Efficacy, and …

WebFind contact information for Dyne Therapeutics. Learn about their Research & Development, Business Services market share, competitors, and Dyne Therapeutics's email format. ... Dyne Therapeutics Top Competitors. Company Employees Revenue Top technologies; Akouos. 57: $19.2 M: Generation Bio. 106: $18.5 M: Leap Therapeutics. … WebDyne Therapeutics Inc is a bio-technology company focused on providing therapeutics for patients with genetically driven diseases. The company is developing therapies for … WebMar 23, 2024 · Dyne Therapeutics is a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases. With its proprietary FORCE™ platform, Dyne is developing modern oligonucleotide therapeutics that are designed to overcome limitations in delivery to … how did fred smith treat his employees

DYN - Dyne Therapeutics Inc Stock quote - CNNMoney.com

Category:Dyne Therapeutics Company Profile: Stock Performance

Tags:Dyne therapeutics competitors

Dyne therapeutics competitors

Dyne Therapeutics Company Profile - Office Locations, …

WebModerna Inc. stock outperforms competitors on strong trading day. MRNA +3.87% COMP +1.97%. MarketWatch · 2 days ago. Analyst. ... Dyne Therapeutics Inc. is a muscle disease company. The Company ... WebDyne Therapeutics Inc 's competitive profile, comparisons of quarterly results to its competitors, by sales, income, profitability, market share by products and services - …

Dyne therapeutics competitors

Did you know?

WebOct 2, 2024 · Dyne Therapeutics Competitors. There are no companies similar to Dyne Therapeutics Dyne Therapeutics Related Companies. ... No industry vertical has been recorded for Dyne Therapeutics View All. Dyne Therapeutics Recommended Market Profiles (6) Telemedicine. 10,000 or More employees. 19 companies. WebApr 4, 2024 · Dyne Therapeutics currently has a consensus target price of $25.83, suggesting a potential upside of 133.79%. Given Dyne Therapeutics’ higher possible upside, equities analysts plainly believe ...

WebFind Dyne Therapeutics stock competitors. Compare other stocks that are similar to DYN in performance, different metrics, and ratios. ... Dyne Therapeutics (DYN) Similar … WebApr 3, 2024 · “ Dyne’s breakthrough approach brings the power of modern oligo therapeutics and other payloads to patients with serious muscle diseases," said Jason Rhodes, a partner at Atlas Venture and ...

WebApr 4, 2024 · 5 brokerages have issued twelve-month target prices for Dyne Therapeutics' shares. Their DYN share price forecasts range from $18.00 to $34.00. On average, they … WebMar 20, 2024 · WALTHAM, Mass., March 20, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on …

WebFeb 9, 2024 · Competitors: Unknown. Dyne Therapeutics Reviews ... Glassdoor gives you an inside look at what it's like to work at Dyne Therapeutics, including salaries, …

WebNov 3, 2024 · Cash position: Cash, cash equivalents and marketable securities were $248.1 million as of September 30, 2024, which is anticipated to fund operations through 2024. Research and development (R&D) expenses: R&D expenses were $34.7 million for the quarter ended September 30, 2024, compared to $36.5 million for the quarter ended … how many seats are there in nit in indiaWebDec 30, 2024 · Peers & Competitors. Follow $11.59 0.19 (+1.67%) 3:59 PM 12/30/22. ... Dyne Therapeutics, Inc. (DYN) key stats comparison: compare with other stocks by … how many seats are there in vitWebDyne Therapeutics has 5 employees at their 1 location and $165 m in total funding,. See insights on Dyne Therapeutics including office locations, competitors, revenue, … how many seats are there in rajya sabhaWebSep 6, 2024 · Dyne Therapeutics is a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases. With its proprietary FORCE™ platform, Dyne is developing modern oligonucleotide therapeutics that are designed to overcome limitations in delivery to … how did fred weasley die in harry potterWebDyne Therapeutics is a public company that has been in the industry for 6 years. The company currently specializes in the Biotechnology, Biotechnology, Pharmaceuticals areas. The position of the President & CEO is occupied by Joshua Brumm. Its headquarters is located at Waltham, Massachusetts, USA. The number of employees ranges from 25 to … how did fred weasley dieWebApr 6, 2024 · 91,5%. More Financials. Company. Dyne Therapeutics Inc. is a muscle disease company. The Company is focused on advancing therapeutics for patients with genetically driven diseases. It is utilizing its FORCE platform to overcome the limitations of muscle tissue delivery and oligonucleotide therapeutics for muscle diseases. how did frederick the wise dieWebAug 1, 2024 · Dyne Therapeutics: ClinicalTrials.gov Identifier: NCT05481879 Other Study ID Numbers: DYNE101-DM1-201 2024-000889-18 ( EudraCT Number ) First Posted: August 1, 2024 Key Record Dates: Last Update Posted: April 7, 2024 Last Verified: April 2024 Individual Participant Data (IPD) Sharing Statement: ... how did freed slaves get their last names